Karlin Daniel sold $397K of DFTX

Karlin Daniel (Chief Medical Officer) sold 10,853 shares of Definium Therapeutics, Inc. (DFTX) at $36.57 ($0.40M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Karlin Daniel
Published Sep 30, 2026, 1:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 1:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DFTX
Bearish
medium confidence
Mentioned
$DFTX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DFTXBearishLow
01

Why it matters

Provides fresh, primary‑source data on insider holdings, useful for short‑term sentiment assessment.

02

Market read

Insider sale of ~0.4 M USD may cause slight price dip; relevance limited to DFTX shareholders.

03

What to watch

Potential upcoming clinical data or financing events that may offset the sell‑off.

Relevance 3/10Novelty 3/10Timing: after market close (Form 4 filed Sep 29)

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$DFTXBearishMedium confidence
Context

Chief Medical Officer sold 10,853 shares for $396,894 via a 10b5‑1 plan, reducing his stake to 792,846 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

The transaction size (~$0.4 M) is modest for a mid‑cap biotech, but a CMO sale via a pre‑arranged plan can be interpreted as a lack of confidence.

Market effects

Minor impact on biotech sector; no broader industry signal.

Limited to US biotech investors.

Low; does not affect global markets.

Counterpoint

The sale could be routine execution of a pre‑arranged plan, not a negative signal.

Key entities

  • Definium Therapeutics, Inc.

    Biotech firm developing therapeutics; ticker DFTX.

  • Karlin Daniel

    Chief Medical Officer of Definium Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DFTXHighAI 8/10

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Definium Therapeutics (DFTX) reported positive results from early studies of its LSD treatment for autism, showing consistent effects in participants. The company plans to file for FDA approval after completing Phase 3 studies. Definium is also addressing safety concerns and plans to study individuals with more profound impairments. The company's lead products include MM120 and DT402, currently in clinical trials for various disorders.

$DFTXMedAI 8/10

Definium (DFTX) Q3 2026 Earnings Call Transcript

Definium (DFTX) reported Q3 2026 earnings, highlighting FDA breakthrough therapy designations for DT120. The company plans an NDA filing in H1 2027 and shared positive clinical data for DT120 and DT402. DT120 showed significant improvements in anxiety and depression trials, with plans to expand into PTSD. DT402 showed early promise in autism spectrum disorder studies. The company is preparing for a potential launch, focusing on commercial infrastructure and provider engagement.

$DFTXMed

What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call

Definium Therapeutics (DFTX) reported Q3 earnings, highlighting progress in clinical trials for DT120 and DT402. DT120 showed tolerability in Phase 3 studies, with top-line results for Ascend expected in 2027. DT402's early autism study was halted after five participants showed consistent efficacy signals. R&D expenses rose to $46.1M, with a net loss of $51M, narrower than the previous year. The company plans commercial preparations for DT120, targeting a pricing range of $30,000-$75,000.

$DFTXHighAI 8/10

Why is Definium Therapeutics stock gaining today?

Definium Therapeutics (DFTX) shares rose 0.2% after reporting Q3 2026 results. The company narrowed its net loss to $50.96M, reported positive Phase 3 results for DT120 ODT in anxiety, and received FDA Breakthrough Therapy Designation for depression. Cash reserves increased to $1.05B. Analysts maintain a Buy consensus with raised price targets.

$DFTXHigh

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent

Definium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT